EP0526545A1 - Isoquinoline amides and esters as 5 ht3 receptor antagonists - Google Patents

Isoquinoline amides and esters as 5 ht3 receptor antagonists

Info

Publication number
EP0526545A1
EP0526545A1 EP91908698A EP91908698A EP0526545A1 EP 0526545 A1 EP0526545 A1 EP 0526545A1 EP 91908698 A EP91908698 A EP 91908698A EP 91908698 A EP91908698 A EP 91908698A EP 0526545 A1 EP0526545 A1 EP 0526545A1
Authority
EP
European Patent Office
Prior art keywords
compound according
formula
alkyl
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91908698A
Other languages
German (de)
English (en)
French (fr)
Inventor
Francis D. Smithkline Beecham Pharmaceut. King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of EP0526545A1 publication Critical patent/EP0526545A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • This invention relates to novel compounds having useful pharmacological properties, to pharmaceutical compositions containing them, to a process and intermediates for their preparation, and to their use as pharmaceuticals.
  • GB 2145416A (Sandoz Ltd) describes a group of naphthylene, chromene and quinoline derivatives with saturated
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:
  • E is NH or O
  • R 1 is hydrogen, halogen, C 1 -4 alkyl, C 1-4 alkoxy, hydroxy or nitro;
  • Z is an azacyclic or azabicyclic side chain, such as a group of formula (a), (b) or (c):
  • R 3 or R 4 is hydrogen or C 1-4 alkyl, and Y is a group
  • R 2 is in the 3-position and is hydrogen, C 1 -6 alkyl or C 1 -6 alkoxy, or R 2 is in the 4-position and is hydrogen, halogen, CF 3 , C 1 -6 alkyl, C 1 -7 acyl, C 1 -7 acylamino, phenyl optionally substituted by one or two C 1 -6 alkyl, C 1 -6 alkoxy or halogen groups, or amino, aminocarbonyl or aminosulphonyl, optionally
  • Suitable examples of the group R 1 include hydrogen 7 bromo, chloro, methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl, methoxy, ethoxy, n- and iso-propoxy, and n-, iso-, sec- and tert-butoxy.
  • Suitable examples of Z are described in the art relating to 5-HT 3 receptor antagonists, ie. as follows: i) GB 2125398A (Sandoz Limited)
  • EP-A-215545 (Beecham Group p. I.e.)
  • EP-A-214772 (Beecham Group p. I.e.)
  • R is hydrogen or methyl; and X is oxygen or sulphur.
  • Side chains Z of particular interest include tropane and oxagranatane, where R is methyl.
  • E is preferably NH.
  • suitable examples of the group R 2 when in the 4-position include the
  • alkanoylamino such as formylamino, acetylamino,
  • propionylamino, n- and iso-butyrylamino, aminosulphonyl, and amino and aminosulphonyl optionally substituted by one or two methyl, ethyl, n- or iso-propyl, n-, sec-, iso- or
  • tert-butyl or phenyl groups nitro, methoxy, ethoxy, n- and iso-propoxy, methylthio, ethylthio, n- and iso-propylthio, hydroxy, methylsulphonyl and ethylsulphonyl or when R 2 is in the 3-position suitable examples, include the following groups, hydrogen, methyl, ethyl, n- or iso-propyl, methoxy, and ethoxy.
  • examples of the group R 2 when in the 1-position include the groups hydrogen, methyl, ethyl, n- or iso- propyl, methoxy and ethoxy, or when R 2 is in the 4-position, suitable examples include the following groups; hydrogen, methoxy and ethoxy.
  • R 2 groups in any of the positions specified above, include hydrogen, methyl and methoxy.
  • R 3 /R 4 when alkyl are methyl, ethyl, n- and
  • p, q and r are 1 or 2.
  • the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with
  • the pharmaceutically acceptable salts of the compounds of the formula (I) are usually acid addition salts with acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.
  • Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R a -T wherein R a is C 1 -6 alkyl, phenyl-C 1 -6 alkyl or C 5 -7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
  • R a include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl, preferably methyl.
  • Suitable examples of T include halide such as chloride, bromide and iodide.
  • Examples of pharmaceutically acceptable salts of compounds of formula (I) also include internal salts such as
  • N-oxides pharmaceutically acceptable N-oxides.
  • the compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable
  • a group of compounds within formula (I) is of formula (II):
  • a further group of compounds within formula (I) is of formula (III):
  • the invention also provides a process for the preparation of a compound of formula (I) which process comprises reacting a compound of formula (V):
  • a 1 and A 2 are, for example, as described in the aforementioned patent publications.
  • a 1 may be an actived carbonyl function such as an acid chloride or N-hydroxysuccinmide ester and A 2 may be an amino group, when E in formula (I) is NH.
  • Intermediates of the formula (V) are generally known or are prepared by analogous methods to those used for structurally related known compounds.
  • Intermediates of formula A 2 -Z' may be prepared from the corresponding exocyclic keto derivative of the azabicyclic side chain, prepared by condensation methods, often using a substituted piperidine, as described in the aforementioned patent references.
  • the invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (VI):
  • R 3 ' and R 4 ' respectively is R 3 and R 4
  • Examples of leaving groups Q, displaceable by a nucleophile include halogen such as chloro and bromo, C 1-4 alkoxy, such as CH 3 O and C 2 H 5 O-, PhO-, or activated hydrocarbyloxy, such as Cl 5 C 6 O- or COQ forms a mixed anhydride, so that Q is carboxylic acyloxy.
  • halogen such as chloro and bromo
  • C 1-4 alkoxy such as CH 3 O and C 2 H 5 O-, PhO-
  • activated hydrocarbyloxy such as Cl 5 C 6 O- or COQ forms a mixed anhydride, so that Q is carboxylic acyloxy.
  • a group Q is a halide or COQ forms a mixed anhydride
  • the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as benzene, dichloromethane, toluene, diethyl ether,
  • tetrahydrofuran THF
  • DMF dimethylformamide
  • an acid acceptor such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as the solvent.
  • the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate.
  • reaction is preferably carried out in an inert polar solvent, such as toluene or
  • a group Q is hydroxy
  • the reaction is generally carried out in an inert non-hydroxylic solvent, such as dichloromethane, THF or DMF optionally in the presence of a dehydrating agent such as a carbodiimide, for example dicyclohexylcarbodiimide, optionally in the presence of N- hydroxysuccinimide.
  • a dehydrating agent such as a carbodiimide, for example dicyclohexylcarbodiimide, optionally in the presence of N- hydroxysuccinimide.
  • the reaction may be carried out at any non-extreme temperature, such as -10 to 100°C, for example, 0 to 80°C. Generally, higher reaction temperatures are employed with less active compounds whereas lower
  • acyloxy leaving groups include C 1-4 alkanoyloxy and C 1 -4
  • alkoxycarbonyloxy in which case the reaction is preferably carried out in an inert solvent, such as dichloromethane, at a non-extreme temperature for example ambient temperatures in the presence of an acid acceptor, such as triethylamine.
  • C 1 -4 alkoxycarbonyloxy leaving groups may be generated in situ by treatment of the corresponding compound wherein Q is hydroxy with a C 1-4 alkyl chloroformate.
  • a group Q is activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as dimethylformamide. It is also preferred that the activated hydrocarbyloxy group is a pentachlorophenyl ester and that the reaction is carried out at ambient temperature.
  • R 3 ' and R 4 ' when other than R 3 and R 4 respectively, may be a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from halo, C 1-4 alkoxy and C 1 -4 alkyl. Such benzyl groups may, for example, be removed, by conventional transition metal catalysed hydrogenolysis to give compounds of the formula (VII) or (VIII) respectively:
  • This invention also provides a further process for the preparation of a compound of the formula (I) wherein Z is a) or c) or a pharmaceutically acceptable salt thereof, which comprises N-alkylating a compound of formula (VII) or (VIII) respectively, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula (I).
  • N-alkylation' comprises the substitution of the N-atom depicted in formula (VII) or (VIII) respectively, by a group R 3 or R 4
  • Suitable values for Q 3 include groups displaced by
  • nucleophiles such as Cl, Br, I, OSO 2 CH 3 or OSO 2 C 6 H 4 pCH 3 .
  • Favoured values for Q 3 include Cl, Br and I.
  • the reaction may be carried out under conventional
  • alkylation conditions for example in an inert solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.
  • an acid acceptor such as potassium carbonate.
  • the reaction is carried out at non-extreme temperature such as at ambient or slightly above.
  • 'N-alkylation' may be effected under
  • the compounds of formula (VI) are known or are preparable analogously to, or routinely from, known isoquinoline compounds.
  • the -COE- linkage has an endo orientation with respect to the ring of the bicyclic moiety to which it is attached.
  • a mixture of endo and exo isomers of the compound of the formula (I) may be synthesised non-stereospecifically and the desired isomer separated conventionally therefrom e.g. by chromatography; or alternatively the endo isomer may if desired by synthesised from the corresponding endo form of the compound of the formula (II).
  • isoquinuclidine isogranatane, oxa/thia-isogranatane and isotropane side chains.
  • compositions of this invention may be formed conventionally.
  • the acid addition salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable organic or inorganic acid.
  • the compounds of the present invention are 5-HT 3 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders and gastrointestinal disorders. Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes in particular that of preventing vomiting and nausea associated with cancer therapy, and motion sickness. Examples of such cancer therapy include that using cytotoxic agents, such as cisplatin, doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment.
  • CNS disorders include anxiety, psychosis, senile dementia and drug dependence.
  • Gastrointestinal disorders include irritable bowel syndrome and diarrohea.
  • 5-HT 3 receptor antagonists may also be of potential use in the treatment of obesity and/or arrhythmia.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid
  • compositions preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
  • Orally administrable compositions are preferred, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional
  • excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art, for example with an enteric coating.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats,
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats,
  • emulsifying agents for example lecithin, sorbitan
  • non-aqueous vehicles which may include edible oils, for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
  • the oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by
  • a surfactant or wetting agent is included in the composition to facilitate uniform
  • the invention further provides a method of treatment or prophylaxis of pain, emesis, CNS disorders and/or
  • gastrointestinal disorders in mammals such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
  • a unit dose for a 70kg adult will normally contain 0.05 to 1000mg for example 0.1 to 500mg, of the compound of the invention.
  • Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of
  • the invention also provides a pharmaceutical composition for use in the treatment and/or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders which
  • composition comprises an effect non-toxic amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of pain, emesis, CNS disorders and/or
  • the invention further provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prophylaxis of pain, emesis, CNS disorders and/or
  • Compounds are given intravenously and the concentration required to reduce the 5-HT-evoked response to 50% of the control response (ED 50 ) is then determined.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP91908698A 1990-04-27 1991-04-22 Isoquinoline amides and esters as 5 ht3 receptor antagonists Withdrawn EP0526545A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9009542 1990-04-27
GB909009542A GB9009542D0 (en) 1990-04-27 1990-04-27 Novel compounds

Publications (1)

Publication Number Publication Date
EP0526545A1 true EP0526545A1 (en) 1993-02-10

Family

ID=10675130

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91908698A Withdrawn EP0526545A1 (en) 1990-04-27 1991-04-22 Isoquinoline amides and esters as 5 ht3 receptor antagonists

Country Status (11)

Country Link
EP (1) EP0526545A1 (enrdf_load_html_response)
JP (1) JPH05507071A (enrdf_load_html_response)
AU (1) AU7753991A (enrdf_load_html_response)
CA (1) CA2081350A1 (enrdf_load_html_response)
GB (1) GB9009542D0 (enrdf_load_html_response)
IE (1) IE911399A1 (enrdf_load_html_response)
NZ (1) NZ237957A (enrdf_load_html_response)
PT (1) PT97490A (enrdf_load_html_response)
TW (1) TW199157B (enrdf_load_html_response)
WO (1) WO1991017161A1 (enrdf_load_html_response)
ZA (1) ZA913123B (enrdf_load_html_response)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05310732A (ja) * 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
IT1303123B1 (it) 1998-10-13 2000-10-30 Rotta Research Lab Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
EP1432707B1 (en) 2001-10-02 2012-03-28 Pharmacia & Upjohn Company LLC Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
MXPA04008152A (es) 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
EP1476449A1 (en) 2002-02-19 2004-11-17 PHARMACIA &amp; UPJOHN COMPANY Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
CA2475773A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
EP2557080A1 (en) 2006-04-04 2013-02-13 The Regents of The University of California Method for identifying pI3-kinase antagonists
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
NZ613219A (en) 2008-01-04 2014-11-28 Intellikine Llc Heterocyclic containing entities, compositions and methods
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2817577A1 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101875720B1 (ko) 2011-01-10 2018-07-09 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2900673A4 (en) 2012-09-26 2016-10-19 Univ California IRE1 MODULATION
WO2014071109A1 (en) 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR102365651B1 (ko) 2013-10-04 2022-02-21 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
EP3350183B1 (en) 2015-09-14 2025-04-02 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352802A (en) * 1980-06-10 1982-10-05 Beecham Group Limited Bicyclo[3.3.1]nonyl-benzamide
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
EP0126087A1 (en) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl derivatives as dopamine antagonists
ATE86110T1 (de) * 1984-12-20 1993-03-15 Sandoz Ag Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9117161A1 *

Also Published As

Publication number Publication date
GB9009542D0 (en) 1990-06-20
AU7753991A (en) 1991-11-27
TW199157B (enrdf_load_html_response) 1993-02-01
PT97490A (pt) 1992-01-31
NZ237957A (en) 1993-09-27
CA2081350A1 (en) 1991-10-28
ZA913123B (en) 1992-05-27
WO1991017161A1 (en) 1991-11-14
IE911399A1 (en) 1991-11-06
JPH05507071A (ja) 1993-10-14

Similar Documents

Publication Publication Date Title
EP0526545A1 (en) Isoquinoline amides and esters as 5 ht3 receptor antagonists
EP0255297B1 (en) Azabicyclic compounds, process for their preparation, and their pharmaceutical use
US4937247A (en) 1-acyl indazoles
EP0200444B1 (en) Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
EP0315390B1 (en) Novel 4-oxobenzotriazines and 4-oxoquinazolines
AU626614B2 (en) 9-aza-3(oxa or thio)bicyclo(3.3.1)nonane derivatives
IE60111B1 (en) Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
EP0254584B1 (en) Azabicyclic compounds, process for their preparation, and their pharmaceutical use
EP0223385B1 (en) 8-Azabicyclo[3,2,1]octane and 9-azabicyclo[3,3,1]nonane derivatives
EP0289170B1 (en) Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP0261964A2 (en) Azabicyclic compounds and their use as 5-ht3 receptor antagonists
WO1993008185A1 (en) N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
US5049556A (en) Certain N-azabicyclo-2,3-dihydro-indole-1-carboxamides having anti-emetic properties, further found useful in treating headaches, neuralgia and anxiety
WO1992011259A1 (en) Azabicyclic amides or esters of halogenated benzoic acids
AU651645B2 (en) Pharmaceuticals
WO1991001316A1 (en) New 9-azabicyclo[3.3.1]nonane-derivate
WO1993008186A1 (en) Pyridine-3-carboxylic acid esters or amides useful as 5-ht3 antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950818